Haleon (HLNCF) Return on Capital Employed (2023)
Haleon (HLNCF) recorded quarterly Return on Capital Employed of 7.62% in Q4 2023.
Haleon (HLNCF) Return on Capital Employed (2023) Analysis & Trends
Haleon has disclosed Return on Capital Employed across 1 years of filings, most recently posting 7.62% for Q4 2023.
- Quarterly Return on Capital Employed changed N/A year-over-year to 7.62% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 7.62% (changed N/A YoY) and the FY2025 annual result came in at 8.61%, up 71.0% from the prior year.
- Return on Capital Employed held at 7.62% in Q4 2023.
- Over five years, Return on Capital Employed peaked at 7.62% in Q4 2023 and troughed at 7.62% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Haleon | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.62% |